BenevolentAI
late ben atopic dermatitis phase i part a completes phase i part tes asset ready for out licensing ben ulcerative colitis candidate nominated for enabling studies reg tox completed phase i starts early collaboration in new targets selected by and further targets selected and advanced pipeline depth and progression programmes named chemistry and beyond new targets added to the pipeline per year from up to assets enter enabling studies onwards platform collaborations exploratory discussions with numerous parties underway but timing unclear multiple value in milestones in the near future late ben atopic dermatitis ben ulcerative colitis collaboration pipeline depth and progression other platform collaborations inflection | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
38 of 42
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Presentation
June 2022
multiple value inflection milestones expected | BenevolentAI
Related slides by other companies
23andMe
Investor Presentation
January 2024
therapeutics pipeline first in class potential | 23andMe
GH Research
Investor Presentation
March 2023
pipeline | GH Research
AstraZeneca
Investor Presentation
March 2022
early pipeline news flow | AstraZeneca
Theravance Biopharma
Results
February 2023
targets | Theravance Biopharma
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io